**Title: Analysis of under-reporting of Adverse Drug Reaction: Scenario in India and few other countries**

**Authors:**

1. Anupam Banerjee

2. Shrobona Basu

3. Avisek Dutta

**Corresponding Author**

Avisek Dutta

(Independent Researcher)

Tel: +91 8451841129

Email: [pvreview2019@gmail.com](mailto:pvreview2019@gmail.com)

Address-27/2 New Ballygunge Road, Kolkata-700039

***Abstract:***

*Adverse Drug Reaction (ADR) is a noxious and unintended response to a medicine which occurs at doses normally used in human being. Pharmacovigilance (PV) is the process to monitor patient safety in practical condition and analyse adverse events during the entire life cycle of a drug beginning from its trial phase to post marketing of the drug. Before medicines get authorised, they are tested in controlled trial conditions within a smaller population for a limited length of time. Post authorization, drugs are used by a larger population across various geographies without any control in place. So, it is very important to monitor adverse effect caused by these medicines throughout their life cycle in order to identify and minimize risks associated with the use of drug and enhance the knowledge of healthcare professionals. However under reporting is a major obstacle in the PV system. Research shows that the major causes of under reporting are lack of knowledge and awareness among healthcare professionals and also absence of established ADR reporting system in various part of the world. Some other reasons of underreporting included large number of patients, poor doctor-patient ratio and common practice of self-medication. This article reviews the research done on ADR underreporting scenario with a focus on the factors leading to this obstacle in PV.*

**Keywords:**

ADR-Adverse Drug Reaction

PV-Pharmacovigilance

WHO-World Health Organisation

UMC-Uppsala Monitoring Centre

ICH- International Council for Harmonisation

AMC-ADRs Monitoring Centres

AIIMS-All India Institute of Medical Sciences

CDSCO-Central Drugs Standard Control Organization

ICSR- Individual Case Safety Report

FDA- Food and Drug administration

ICH- International Conference on Harmonisation

EMA-European Medicines Agency

PRAC- Pharmacovigilance Risk Assessment Committee

PMDA- Pharmaceuticals and medical Device Agency

**Introduction:**

Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment understanding and prevention of adverse effect or any other drug related problem. WHO established Programme for International Drug Monitoring (PIDM) in 1968, after Thalidomide disaster in 1961. [The](https://en.wikipedia.org/wiki/World_Health_Organization) WHO [Collaborating Centre](https://en.wikipedia.org/wiki/WHO_Collaborating_Centres) for International Drug Monitoring also known as Uppsala Monitoring Centre (UMC) was established in 1978 in Sweden. Currently, 134 countries are part of the WHO PV Programme [1]. Globalization of the pharmaceutical industry has prompted efforts towards harmonisation of PV practices worldwide to enable improved knowledge of medicine's benefit-risk profile and risk communication [2]. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a unique body bringing together regulatory authorities and pharmaceutical industry to discuss scientific and technical aspect of ADR monitoring. ADR are undesirable effects that occur as a result of drug treatment at doses normally used in man for treatment. Although there are many terms indicating the harmful and undesirable effects of drug treatment, the term ‘adverse drug reaction’ describes it most appropriately. ADRs are a common cause of concern to both the physicians and the patients. They not only add to the spiralling costs of disease treatment, but also major cause of morbidity and mortality. However, many observed ADRs go unnoticed in various countries including India. In India, there are certain peculiarities of drug use such as: large number of patients, poor doctor-patient ratio, and self-medication practice, drugs of alternative systems of medicine, malnutrition, presence of counterfeit drugs, and presence of the highest number of combinational products. Therefore, incidence of the adverse drug reactions in India is likely to be same as that of the developed nations, or more. However, in spite of presence of organised ADRs Monitoring Centres (AMC), the number of reports sent annually is negligible. These calls for the urgent need to give a boost to the monitoring of adverse reactions through public education against self-medication, introduction to drug-safety in the curriculum of medical and pharma undergraduates, a systemic and periodic training of health professionals. Multi-prolonged strategy can lead to reduction in the incidence of underreporting [3, 4, 5].

**Methodology:**

The method involved the review of research articles, review articles and other materials from the internet sources. Various journals, articles and reports were thoroughly searched for the analysis of the under reporting of adverse drug reactions in different countries. The information obtained helped to understand the scenario and history of Pharmacovigilance in India and also the scenario in different other countries. Various factors leading to the underreporting of ADR were also identified in the process.

**Adverse Drug Reaction (ADR) reporting Scenario in Various Countries**

***Adverse Drug Reaction (ADR) reporting Scenario in India:***


Pharmacovigilance is an integral part of standard healthcare process, but it is still not widely accepted in India. In various ways, it has been established that ADR causes considerable amount of morbidity and mortality [3]. Yet total number of ADRs reported in India is very few. This is because it is still in a developing phase. As any other developed country in the world, India felt the need of drug safety monitoring. The origin of pharmacovigilance in India goes back to the year 1986, when officially an ADR monitoring system consisting of 12 regional centres was proposed with each centre covering a population of 50 million. However, there was no progress made till 1997 when India joined the WHO Adverse Drug Reaction Monitoring Programme managed by Uppsala Monitoring Centre (UMC). This attempt was again unsuccessful and from November 2004, Government of India launched National Pharmacovigilance Program for India (NPPI) supported by WHO and World Bank. The NPPI was to be overseen by the National Pharmacovigilance Advisory Committee (NPAC) based in the Central Drugs Standard Control Organization (CDSCO), New Delhi. Two zonal centres - the South-West zonal (SW) centre and the North-East (NE) zonal centre were responsible to collate information from all over the country and send it to the Committee as well as to UMC. Under these 2 zonal centres there were 5 regional centres and under 5 regional centres there were 26 peripheral centres. However this program also did not meet up with desirable result. Recognizing the need to restart the National Pharmacovigilance Programme (NPvP), jointly formulated by the Department of Pharmacology, AIIMS and CDSCO in late 2009. After understanding the need for a better ADR reporting system in India, the health ministry launched a programme called Pharmacovigilance Programme of India (PvPI) in the year 2010 [4]. Under this programme, multiple Adverse Drug Reaction Monitoring Centres (AMC) were set up across various cities in India, in all the medical colleges approved by Medical Council of India (MCI) with the AIIMS, New Delhi as the National Coordination Centre (NCC) for monitoring ADRs in the country for safe-guarding public health. In the year 2010, 22 ADR monitoring centres including AIIMS, New Delhi was set up under this programme. To ensure implementation of this programme in a more effective way, the NCC was shifted from the AIIMS to the Indian Pharmacopoeia Commission (IPC), Ghaziabad, Uttar Pradesh on 15 April 2011. Currently, there are around 170 Adverse Drug Reaction Monitoring Centres (AMC) in India. The main function of these AMCs is collection of ADR reports and uploading them in VigiFlow database. Over the last 5 years the National Co-ordinating Centre (NCC) has played an important role in generating awareness for HealthCare Professionals (HCP) on the importance of reporting ADRs. This initiative helped to generate around 149,000 reports by the end of 2015 [6, 7]. However, Indian AMC functional rate was very low compared to the developed nations. Lack of awareness, training and knowledge were marked as key factors affecting the Pharmacovigilance ****programme of India (PvPI).

Fig 1: The number of report received (Solid bar) since the year 2010 until the end of 2015. Growth of Individual Case safety Reports (ICSR) reported since the inception of Pharmacovigilance Programme of India.

**Adverse Drug Reaction (ADR) reporting Scenario in few other countries:**


In USA Food and Drug administration (FDA) has the main responsibility to ensure drug safety. However, the US FDA relies on spontaneous reporting of Adverse Drug Reactions. Studies have shown that underreporting of ADR is widespread [7, 8]. FDA Adverse Drug Event Reporting System (FAERS) was developed to give information related to human ADRs reported to FDA adhering to ICH (International Conference on Harmonisation) guidelines. Like any other standard ICSR database duplicate, incomplete and unverified reports are the main drawbacks of FAER database.

Fig 2: Number of adverse event reports by FDA since 2010 until the end of 2017. Data collected from FAERS dashboard.


EMA coordinates the European Union (EU) pharmacovigilance system. The overall EU pharmacovigilance system operates through co-operation between the EU member states, EMA and European Commission. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring the safety of human medicines. The agency is responsible for developing and maintaining EudraVigilance, a system for managing and analyzing information on suspected adverse reactions to medicines authorised in European Economic area (EEA). The PRAC evaluates safety signals from EudraVigilance and may recommend regulatory action as a consequence [9].

Fig 3: The number of report received since the year 2010 until the end of 2017. Source: EMA annual reports.

Japan has the world’s second largest pharmaceutical market, with annual sales of approximately 70 Billion (USD), after USA. Japan has a sound PV system in place. Pharmaceuticals and medical Device Agency (PMDA) is the responsible agency for PV in Japan. Early Post-Marketing Phase vigilance (EPPV) requires conducting PV for the first 6 months after the launch of a new product in Japan. The objectives of conducting EPPV is to ensure that appropriate information has been provided to prescriber to promote appropriate use of the drug and to minimize the associated public health risk.




Fig 4: The number of report received since the year 2011 until the end of 2017. Source: PMDA reports.

Health Canada had established ADR reporting system for Healthcare Professionals. However this is also a Passive System and requires voluntary participation which is characterised by low number of reporting. Data from Canadian Burn treatment Centres and Canadian Institute for Health Information (CIHI) for the period between 1995 and 2000 shows that only 4% to 10% of cases identified were reported to Canadian Adverse Drug Reaction Monitoring Program (ADRMP) [10]. Deficiencies in Canada spontaneous reporting system (SRS) for adverse drug reaction (ADRs) are caused by underreporting, poor quality information, duplication of report [11]. All reports of ADR associated with the use of registered product occurring in Malaysia must be reported to Drug Control Authority (DCA) within the stipulated timeline. Registration holders who have registered a product containing a New Chemical Entity (NCE) after 1-Jan-2002 must routinely submit Periodic Safety Update Reports (PSUR) on the product for first 2 years post approval in Malaysia and annually for subsequent 3 years [12]. Nearly 75% drugs in Nepal are imported from foreign countries as Nepal has limited capacity in terms of drug manufacturing. Prior to marketing a drug, Department of Drug Administration (DDA), the regulatory authority, thoroughly assesses the drugs on the basis of the data available from other countries. Pharmacovigilance activities are in a preliminary developing stage in Nepal. ADR reporting is mainly confined to the healthcare professionals [13]. In Bangladesh Director General of Drug Administration (DGDA) is plays an active role to ensure safety of patient [14]. In 1996, under guidance of WHO, a cell was established in DGDA. In 1997, Ministry of Health and Family welfare formed ADR Advisory Committee (ADRAC) to evaluate, analyse and make recommendation for solving problems of medicinal hazards due to ADRs. Pakistan has limited resources in the system of healthcare system. Awareness level on ADR reporting was measured among physicians (51%), pharmacists (29.7%) and Nurses (19.3%). The results showed that 65.5% of HCP population observed ADRs amongst them only 57.4% were reported these in their respective hospitals [15]. The number of deaths related to ADR is not known due to underdeveloped process of pharmacovigilance [16].

Table 1: Comparison of Pharmacovigilance System in India and few other countries.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **India** | **United States** | **European Union** | **Japan** | **Canada** | **Malaysia** | **Nepal** | **Bangladesh** | **Pakistan** |
| Regulatory authority responsible for Pharmacovigilance | CDSCO  NCC PvPI  (Pharmacovigilance Programme of India) | FDA  (Food and Drug administration) | EMA (European Medicines Agency) | PMDA  (Pharmaceuticals and Medical Device Agency) | Health Canada | DCA  (Drug Control Authority)  NPRA  (National Pharmaceutical Regulatory Agency) | DDA  (Department of Drug Administration) | DGDA  (Director General of Drug Administration) | DRAP  (Drug Regulatory  Authority of Pakistan) |
| Guidelines/  laws | Drugs and cosmetics Act, 1940 and Rule, 1945 | 21 CFR | GVP  (Good Pharmacovigilance Practice) guidelines | Pharmaceutic and medical device agency law (Dec,2002) | GVP guideline  (GU1-0102) | Control of Drug and cosmetic regulation (1984)  Malaysian Pharmacovigilance Guidelines  (2002) | Drug Act 2035  (1978) | Drug Act,1940 | Drug Act, 1976  Drug regulatory authority of Pakistan Act,2012 |
| Process of reporting | Paper ADR reporting form, Mobile app, via email, fax | Medwatch,  Online through FAERs | Electronic reporting Eudravigilance | Data received from MAH, Patient, HCP through electronic transmission, email, fax, post and through website | Online reporting,  Via telephone, email, fax, MAH | Online reporting via email, fax | ADR reporting form available in all regional pharmacovigilance centres | Form distributed in medical colleges and hospitals | ADR reporting form available in regional pharmacovigilance centres and medical colleges |
| Risk Management System (RMS) | Periodically checking Vigibase,  Communication through press release and newsletters | Risk Management guide map for  Industry GVP and pharmacoepidemological assessment | RMP (Risk Management Plan) must be submitted to EMA by MAH  National competent authority (NCA) in EU can request RMP whenever required | Safety measure taken to minimize risk. Early Post Authorisation Vigilance, use-result survey, Post-Authorisation clinical study | RMP and ICH E2E guideline for Risk evaluation | Routine risk minimization activity and additional risk minimization activity if required | Presence of Risk assessment and management committee | ADRAC  (Adverse drug reaction advisory committee)  Resolve medicines  Safety issues | Presence of Risk assessment and management committee |

**Factors leading to underreporting of ADRs in India:**

Underreporting of ADRs is a major setback in the evaluation of the safety profile of a drug. Various studies have been done to understand the reason behind underreporting of ADRs. The major causes of under-reporting are:

***Lack of proper knowledge of pharmacovigilance*:**

A study conducted among pharmacists in Delhi revealed that 59.46% of the pharmacists lacked a good knowledge regarding pharmacovigilance and 72.30% of the pharmacists did not understand the meaning of ADR and the difference between an ADR and a side effect [17]. In another study involving medical and dental practitioners in Karnataka, only 2.6% of the respondents reported to have received training with reference to ADR reporting and 46.4% of them reported that they had not reviewed even a single article regarding an ADR in a month. It was noted that more than 57.6% doctors had a pharmacovigilance knowledge level of <50% [24].

***Unawareness of reporting centres and unavailability of reporting forms:***

The study among the pharmacists also revealed that most of them were unaware of the reporting centres. Only 13.51% of the pharmacists reported that they had some set procedures of ADR reporting in their organization. Most pharmacists reported ADRs to Physicians, Manufacturing Industries, Department in-charge, Product Management Team, Chief Pharmacist and purchasing department of hospitals which further lowered the possibility of these reports to reach the National Monitoring Centres (NMCs) and Regional Monitoring Centres (RMCs). Only 2.70% of the pharmacists had the ADR reporting forms [17]. Another observational, questionnaire-based study conducted in Hyderabad involving medical doctors working in different fields revealed 93.61% of the medical doctors agreed that ADR reporting forms were not available at their work place. 89.36% of the doctors accepted that they did not have knowledge about ADR reporting centres and 80.85% physicians agreed that they were not adequately trained in ADR reporting [18].

***Problem in identifying possible ADRs*:**

Another prevalent factor affecting underreporting is that the healthcare professionals are not adequately trained in identifying ADRs. Clinicians were seen to face a challenge in identifying an ADR, the suspected drug and separating the relative contributions of drugs and disease processes to a patient’s chief complaint. Furthermore, regulatory-based passive surveillance systems are not set up to provide practical assistance in interpretation of possible ADRs, as a result of which many go unrecognised [21]. It was also seen that having insufficient clinical knowledge among healthcare professionals made it difficult for them to decide whether a finding is an ADR or not. It was observed that among pharmacists, the ones working in the hospitals were more aware of pharmacovigilance, ADRs, expected therapeutic effects of drugs, possible side effects of prescribed drugs and pharmacoeconomics than community pharmacists and medical representatives and hence were more involved in reporting ADRs than the medical representatives and community pharmacists. This may be due to the fact that not all community pharmacists and medical representatives have a pharmacy qualification as compared to hospital pharmacists [17].

***Limitations of direct patient reporting:***

Some healthcare professionals feel that ADRs should be reported by physicians and the pharmacists [18]. However, there are some physicians who support direct ADR reporting by the patients as well. Direct and spontaneous patient reporting offers added value for pharmacovigilance because it can speed up the acquisition of knowledge about ADRs and also because patients have a vested interest in reporting the adverse events affecting their lives [22]. However, the consumers often have limited understanding of the drug safety system and do not have a clear idea of how to report these adverse events and where to report them. Many companies have started using social media as platforms to acquire information related to adverse events shared by consumers. However, social media has not caught on as a sanctioned source of ADR reporting as it is very difficult to interpret [23]. Consumers write whatever they think and unlike reports from physicians, they often describe how the ADRs affect their lives [22, 23] so what we get are mostly bits and pieces of an adverse event. That makes it extremely difficult to evaluate and understand whether it's a reportable event, let alone who to follow up with if it is [23]. Another problem faced with direct reporting by patients is that most often patients are concerned more about the treatment of the ADRs than their reporting [21]. This can be due to the fact that they are not aware of the importance of ADR reporting and how it can in turn affect their lives. Thus, it is important to impart this knowledge of pharmacovigilance in patients as well. This responsibility in turn lies with the physicians, nurses and pharmacists who interact with patients in person. They need to encourage patients to report any adverse effects they might be facing after using a drug and also direct them to the correct authority and facility where the patients can report these reactions. However, the data collected from the questionnaire based study involving pharmacists revealed that the interaction between pharmacists and patients were indeed quite low. 57.43% of the pharmacists informed the patients about the expected therapeutic effects of the drugs they would take while the rest did not. 47.97% of the pharmacists reported that they inform the patients about the likely side effects of their drug treatment. 44.59% of the pharmacists said that patients inform them about the discomfort and side effects experienced by them during or after a drug treatment while 36.49% pharmacists said patients do not interact with them about such effects. Pharmacists should extend their role from just dispensing to a responsible pharmacist who is willing to inform patients about the expected therapeutic effects, dosage regimen, directions for use and possible side effects of drugs. In addition, he should be good listener to receive feedback from patients [17].

**Other factors:**

ADR reporting is voluntary in most countries. It was observed that some physicians do not report ADRs because of the lack of incentives or because they feel they should rather collect the data and publish themselves [20]. Healthcare professionals have also admitted to have not reported adverse reactions due to the fear of legal liabilities, being labelled as careless and fear of admitting harm to patients [20]. They have also cited that the ADR reporting forms are usually quite complicated which makes the process of reporting time consuming [18, 20]. They also have an opinion that only safe drugs are available in the market and one report of adverse effect would not make any difference [20].

**Conclusion:**

Pharmacovigilance is still in a developing phase, especially in India, and there exists very limited knowledge about this discipline. It was interesting to note in one of the studies conducted in Delhi that knowledge, skill and attitude of hospital pharmacists about pharmacovigilance and ADR reporting was the highest. This may be due to their pharmacy education and constant contact with healthcare professionals and patients in the hospital setting. In addition, all of them cleared the stringent selection procedures ensuring good knowledge base while entering the government sector [17]. This shows the importance of increasing awareness of pharmacovigilance among all healthcare professionals and consumers as that would influence the attitude and practice of ADR reporting. Healthcare professionals should periodically be educated about adverse reactions and should be encouraged to report the same [4]. Educational interventions can be targeted at multiple points in the profession like curriculum, internship training, seminars and Continuing Medical Education programmes [24]. Students should be taught principles of drug safety and rational drug use in their undergraduate and postgraduate curriculum. [4]. The National Coordination Centre (NCC) of Indian Pharmacopoeia Commission (IPC) initiated a flagship programme called "Skill Development Programme on Basics and Regulatory Aspects of Pharmacovigilance" in January 2017 at Ghaziabad, The programme was a part of the skill development programme in India under the government’s Pradhan Mantri Kaushal Vikas Yojana to produce and nurture qualified pharmacovigilance personnel for effective pharmacovigilance. It has till date trained 300 healthcare professionals including doctors and pharmacists to acquire requisite skills for furthering the Pharmacovigilance Programme of India (PvPI) in the country. More such initiates should be taken by the government.

Additionally, healthcare professionals should be encouraged to report any suspected adverse events they feel are important irrespective of proof of evidence or absolute certainty on whether it is related to the particular drug. Presence of trained surveillance personnel at hospitals to guide the clinicians would also help them in gaining more confidence in identifying ADRs and reporting them. Furthermore, healthcare professionals should be made aware of the various safety monitoring centres and trained in sending these reports to the appropriate authorities. Healthcare professionals should also be made to realise that reporting of adverse events is a necessity to improve the quality of drugs they prescribe and in turn patient care and hence falls under one of their duties rather than an additional task or burden.

ADR reporting forms should be made readily available in hospitals and pharmacies and should be made relatively simple and easy to fill so that HCPs feel more inclined to report. Physicians, nurses, pharmacists should be trained on how to use these forms and should in turn be asked to guide consumers for direct patient reporting. Patients also need to be educated regarding the meaning of ADR, ADR reporting and its importance. Efforts should be made to make the reporting process by patients simple and straightforward, possibly by providing consumer online reporting forms or interactive tools. The Indian Pharmacopoeia Commission launched the adverse drug reaction reporting android application “ADR PvPI” in 2015 where healthcare professionals and consumers can instantly report adverse reactions due to a particular drug to PvPI from any part of India. Consumers and healthcare professionals should be made aware of such tools and applications whereby they can report any adverse reactions they want to.

Information regarding ADRs change on a daily basis and hence needs to be constantly updated. Most information in drug inserts and textbooks may be outdated and may not reflect the current state of information on ADRs. Hence ADR reporting guidelines should be made available in the form of booklets and posters at conspicuous locations in healthcare facilities and also on the internet to serve as a constant reminder [18]. The new safety information obtained about a drug through this monitoring should be communicated to the health professionals, thus reducing further incidents of ADRs. Feedback from ADR monitoring centres about the causality and severity of ADRs reported by physicians would also encourage them to continue reporting [18]. These measures would increase the faith of HCPs and consumers in the drug safety monitoring system and encourage them to participate more.

The reporting process should also be made anonymous which would reduce the fear of legal obligations. HCPs should be reminded that occurrence of adverse reactions are natural accompaniments of drug treatment due to their inherent properties. They can be prevented through diligent and rational use of drugs. A physician thus cannot be held responsible for the occurrence of such reactions provided he has not been rash or negligent in using them. Therefore, no clinician should refrain from reporting on this basis [4].In most countries, doctors report adverse drug reactions to the authorities on purely voluntary basis. But in some countries they are required to do so legally. By making the process of ADR reporting mandatory, it should definitely increase the number of reports received. In March 2016, a notification was issued to pharmaceutical industries by Drug Controller General of India (DCGI), asking them to put in place a pharmacovigilance system and have a qualified person who would be responsible for the management of pharmacovigilance in the company. With this, pharmaceutical companies are now required to start pharmacovigilance activity which would in turn improve adverse drug reporting (ADR) to PvPI. However, entrusting pharmaceutical companies with the role of post marketing studies of safety and efficacy of their own drugs could have a conflict of interest as post marketing surveillance research can have huge financial implications. The possibility of withdrawing a drug from the market and the potential legal liability related to findings of serious side effects may lead to significant pressure on investigators, institutions and those working directly under contract with pharmaceutical sponsors. It is thus required to minimize conflicts of interest that can introduce bias in research design and reporting by researchers with ties to the industry. Monitoring and research that affect regulation of drugs should be free from industry influence and ought to have integrity. There can also be a conflict of interest when the agency that approves new drugs is also in charge of conducting post marketing studies on those same drugs, the results of which can lead to their withdrawal and could suggest a failure in the approval process. A fully independent agency or centre not involved in the drug approval processes and with no financial interest in drug development would thus be a better decision maker of safety and efficacy of post-marketed drugs [25].

Although another factor observed affecting underreporting was lack of incentives, using financial incentives to stimulate reporting of ADRs should not be widely encouraged as it might lead to over-reporting by some health care workers or reporting of false data in an attempt to obtain financial rewards. ADR reporting should be seen as a fundamental and ethical responsibility of health care workers and measures should be taken to inculcate this culture.

The need to ensure that marketed drugs are safe and effective is of paramount importance and is also a moral obligation of government health and regulatory agencies. Regulators should take a proactive role in shaping safety and effectiveness surveillance and research, and engage in pre-emptive decision-making in order to prevent harm. This decision making is facilitated by the collection of the highest quality of evidence possible. Regulators also have the duty to be transparent with the public and warn people when safety or effectiveness issues are present with a drug. Transparency requires that the decisions and the rationale behind them be communicated to the public in a way that can be understood by them. Moreover, communicating to the public what is not known about the safety and effectiveness profile of a drug is also very important. However, the need to be transparent with the public is often thought to be in tension with the fact that transparency might result in a decline in drug usage. Premature or overly alarmist warnings may negatively impact drug acceptance in the population. But if the public trust is damaged from a lack of transparency, drug usage may again be negatively impacted. Thus, while there is a moral obligation to provide all relevant information about drug safety and effectiveness to the public in the interests of respecting individual autonomy and promoting informed consent, this must be balanced with the need to prevent and treat diseases [26].

**Author Conflict of Interest Statements:**

a) *Anupam Banerjee* has no conflict of interests to declare in relation to the work presented in this manuscript.

b) *Shrobona Basu* has no conflict of interests to declare in relation to the work presented in this manuscript.

c) *Avisek Dutta* has no conflict of interests to declare in relation to the work presented in this manuscript.

**References:**

1. Pharmacovigilance [Internet]. World Health Organization. [cited 25 February 2019]. Available from:https://www.who.int/medicines/areas/quality\_safety/safety\_efficacy/pharmvigi/en/

2. Hans M, Gupta SK. Comparative evaluation of pharmacovigilance regulation of the United States, United Kingdom, Canada, India and the need for global harmonised practices. Perspect Clin Res. Oct-Dec;9(4):170-4.

3. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002 Apr;24(2):46-54.

4. Dhikav V, Singh S. Adverse Drug Reaction Monitoring In India. Indian academy of Clinical Med. 2004 March;5(1):27-33.

5. Kalaiselvan V, Thota P, Singh G. Pharmacovigilance Programme of India: Recent developments and future perspectives. Indian Journal of Pharmacology. 2016;48(6):624.

6. Tandon V, Mahajan V, Khajuria V, Gillani Z. Under-reporting of adverse drug reactions: A challenge for pharmacovigilance in India. Indian Journal of Pharmacology. 2015;47(1):65.

7. Wang J, Ali E, Gong Y. An Information Enhanced Framework for Reporting Medication Events. Stud Health Technol Inform. 2018;250:169-173.

8. Pushkin R, Frassetto L, Tsourounis C, Segal ES, Kim S. Improving the Reporting of Adverse Drug Reactions in the Hospital Setting. Postgraduate Medicine. 2010;122(6):154–64.

9. Human medicines: regulatory information | European Medicines Agency [Internet]. Ema.europa.eu. 2019 [cited 25 February 2019].

Available from: <https://www.ema.europa.eu/en/human-medicines-regulatory-information>

10. Mittmann N, Knowles S, Gomez M, Fish J, Cartotto R, Shear N. Evaluation of the Extent of Under-Reporting of Serious Adverse Drug Reactions. Drug Safety. 2004;27(7):477-487.

11. Rawson NS. Canada’s Adverse Drug Reaction Reporting System: A Failing Grade. Journal of population therapeutics and clinical pharmacology. 2015 Jan 1;22(2).

12. Biswas P. Pharmacovigilance in Asia. Journal of pharmacology & pharmacotherapeutics. 2013 Dec;4(Suppl1):S7.

13. Jha N, Rathore DS, Shankar PR, Bhandary S, Pandit RB, Gyawali S, Alshakka M. Effect of an educational intervention on knowledge and attitude regarding pharmacovigilance and consumer pharmacovigilance among community pharmacists in Lalitpur district, Nepal. BMC research notes. 2017 Dec;10(1):4.

14. Al-Muntasir M, Saha D, Paul S, Rahim ZB, Hosen SZ. Studies on pharmacovigilance in Bangladesh: Safety issues. Int J Pharm Teach Pract. 2013;4:613-21.

15. Shamim S, Sharib SM, Malhi SM, Muntaha SU, Raza H, Ata S, Farooq AS, Hussain M. Adverse drug reactions (ADRS) reporting: awareness and reasons of under-reporting among health care professionals, a challenge for pharmacists. SpringerPlus. 2016 Dec;5(1):1778.

16. Mahmood KT, Amin F, Tahir M, Haq IU. Pharmacovigilance-A need for best patient care in Pakistan. A review. Journal of Pharmaceutical Sciences and Research. 2011 Nov 1;3(11):1566.

17. Amrita P, Roomi MT. Scenario of pharmacovigilance and ADR reporting among pharmacists in Delhi. Indian Jornal of Pharmacy Practice. 2011;4(4).

18. Kamtane RA, Jayawardhani V. Knowledge, attitude and perception of physicians towards adverse drug reaction (ADR) reporting: A pharmacoepidemiological study. Asian J Pharm Clin Res. 2012;5(3):210-4.

19 Sivadasan S, Chyi NW, Ching AL, Ali AN, Veerasamy R, Marimuthub K, Arumugama DS. Knowledge and perception towards pharmacovigilance and adverse drug reaction reporting among medicine and pharmacy students. World J Pharm Pharm Sci. 2014 Jan 8;3(3):1652-76.

20. Rishi RK, Patel RK, Bhandari A. Under reporting of ADRs by medical practitioners in India—results of pilot study. Adv Pharmacoepidem Drug Saf. 2012;1(3):112.

21. Carleton BC, Smith MA. Drug safety: Side effects and mistakes or adverse reactions and deadly errors?. British Columbia Medical Journal. 2006 Sep;48(7):329.

22. Rishi RK, Patel RK, Bhandari A. Opinion of physicians towards adverse drug reactions reporting results of pilot study. Journal of Community Nutrition & Health. 2012;1(1):25.

23. Adding rigor to the adverse event reporting process [Internet]. Pharmaceutical Commerce. 2019 [cited 2 February 2019]. Available from: https://pharmaceuticalcommerce.com/special-report/adding-rigor-to-the-adverse-event-reporting-process/

24 Praveen S, Prakash R, Manjunath GN, Gautham MS, Kumar N. Adverse Drug Reaction reporting among medical and dental practitioners: a KAP study. Indian Journal of Medical Specialities. 2013 Jan 1;4(1).

25. Ferris L.E, Lemmens T. Governance of conflicts of interest in postmarketing surveillance research and the Canadian Drug Safety and Effectiveness Network. Open Medicine 2010; 4(2):e123.

26. Thompson A, Komparic A, Smith M.J. Ethical considerations in post-market-approval monitoring and regulation of vaccines. Vaccine 32 (2014) 7171–7174.